|
Main | | | | | | | | | | | | | | | |
| Brand Name | Natrecor | | | | | | | | | | | | | |
| Generic Name | nesiritide | | | | | | | | | | | | | |
| Mechanism | Human BNP - relaxes arterial and veinous tissue | | | | | | | | | | | | | |
| Pharmacokinetics | t1/2=18 mins, 2/3 AUC | | | | | | | | | | | | | |
| Administration | IV | | | | | | | | | | | | | |
| Label | http://www.natrecor.com/natrecor/assets/pdf/natrecor_pi.pdf | | | | | | | | | | | | | |
| Indication | adCHF (acutely decompensated congestive heart failure) | | | | | | | | | | | | | |
| IP | Approved 8/10/01, Composition patent | | | | | | | | | | | | | |
| Side Effects | In May 2005, the publication of two medical journal articles linking Natrecor to kidney problems higher death rates than standard heart failure treatments gave rise to a growing controversy about the safety of Natrecor. | | | | | | | | | | | | | |
| Competition | nitroglycerin | | | | | | | | | | | | | |
| Economics | 100%? | | | | | | | | | | | | | |
| Clinical Studies | | | | | | | | | | | | | | |
| | 10 clinical trials | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | Q203 | Q303 | Q403 | FY03 | | | | | FY04 | | | | | FY05 |
| | 30 | 50 | 72 | 152 | 82 | 92 | 92 | 125 | 391 | 110 | 74 | 35 | 30 | 249 |
| | | | | | | | | | | | | | | |
| | Q106: significant decline due to media coverage | | | | | | | | | | | | | |